Anti-Lassa Virus, Nucleoprotein [Clone 1LV13] – Biotin
Anti-Lassa Virus, Nucleoprotein [Clone 1LV13] – Biotin
Product No.: L359
- -
- -
Clone 1LV13 Target Nucleoprotein Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Lassa, LASV, Lassa hemorrhagic fever, Lassa fever virus Isotype Mouse IgG1 κ Applications ELISA , Lateral Flow , WB |
- -
- -
Antibody DetailsProduct DetailsReactive Species Lassa Virus Host Species Mouse Product Concentration 0.5 mg/ml Purity ≥90% Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. State of Matter Liquid Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Applications and Recommended Usage? Quality Tested by Leinco ELISA, WB Additional Applications Reported In Literature ? Lateral Flow Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Anti-Lassa Virus (Clone ILV13) is specific for the Nucleoprotein of Lassa Virus. Background Lassa virus, a member of the Arenaviridae family, is a zoonotic pathogen primarily found in West Africa, particularly in regions such as Nigeria, Sierra Leone, and Liberia. The virus is transmitted to humans primarily through contact with rodent excreta or consumption of contaminated food. Lassa fever, the disease caused by the virus, manifests with flu-like symptoms initially but can progress to severe complications including hemorrhage and organ failure. Timely diagnosis is crucial for effective management, typically involving laboratory tests such as enzyme-linked immunosorbent assay (ELISA) or reverse transcriptase-polymerase chain reaction (RT-PCR) to detect viral antigens or genetic material in blood or tissue samples. Early detection allows for prompt treatment with antiviral medications and supportive care, significantly improving patient outcomes and reducing mortality rates associated with Lassa fever. Research Area Category A Pathogens . Infectious Disease . Matched Pair . Viral . IVD Raw Material References & Citations1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB). Link Technical Protocols Lateral Flow  Certificate of Analysis |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
